Machine Learning Identifies Novel Candidates for DrugRepurposing in Alzheimer's Disease
Steve Rodriguez, Clemens B. Hug, Petar V. Todorov, Nienke Moret, Sarah A. Boswell, Kyle E. Evans, George Zhou, Nathan T. Johnson, Bradley T. Hyman, Peter Karl Sorger, Mark W. Albers, Artem Sokolov
The paper presents a machine learning framework to identify FDA-approved drugs for repurposing in Alzheimer's Disease by analyzing gene lists associated with disease severity and molecular mechanisms.
Nature Communications · Feb 15, 2021Peer-reviewedNeuroscience